Quarterly report pursuant to Section 13 or 15(d)

Research and Development Collaboration Agreements - Additional Information (Detail)

v3.8.0.1
Research and Development Collaboration Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 71 Months Ended
Jun. 23, 2017
USD ($)
Jun. 30, 2017
Target
Oct. 31, 2016
USD ($)
Nov. 30, 2011
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Research And Development Collaboration Agreements [Line Items]                  
Collaboration revenue           $ 0   $ 0  
Grant revenue         $ 0 0 $ 167,000 1,526,000  
Takeda Pharmaceuticals Inc                  
Research And Development Collaboration Agreements [Line Items]                  
Aggregate purchase price $ 20,000,000                
Takeda Pharmaceuticals Inc | Takeda Collaboration Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Threshold period to negotiate and obtain worldwide license     30 days            
Upfront fee receivable     $ 2,000,000            
Collaboration revenue         600,000   1,900,000    
Takeda Pharmaceuticals Inc | Takeda Multi-Target Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Collaboration revenue         0   0    
Number of targets of interest as focus of research. | Target   2              
Threshold period to obtain exclusive license under intellectual property rights agreement   3 months              
Upfront fee received             1,000,000    
Additional fee received upon designation of each of two targets         2,000,000   2,000,000   $ 2,000,000
Net milestone payments receivable, through exercise of option to license         25,000,000   25,000,000   25,000,000
Additional milestone payments receivable, post option exercise         545,000,000   $ 545,000,000   545,000,000
License agreement termination description             The Takeda Multi-Target Agreement will expire on the expiration of the option period (within three months after the completion of the evaluation of each designated target) for the designated targets if Takeda does not exercise its options, or, following exercise of the option, on the later of the expiration of patent rights claiming the licensed ETB or ten years from first commercial sale of a licensed ETB. Takeda Multi-Target Agreement may be sooner terminated by Takeda for convenience or upon a Molecular change of control, or by either party for an uncured material breach of the agreement.    
License agreement termination period, if license not obtained             3 months    
License agreement termination period from first commercial sale             10 years    
Aggregate purchase price         20,000,000        
Cancer Prevention and Research Institute of Texas | Grant Agreements | Product Development Grant | ETB MT-3724                  
Research And Development Collaboration Agreements [Line Items]                  
Grant funds       $ 10,600,000         $ 9,500,000
Grant revenue         $ 0 $ 0 $ 200,000 $ 1,500,000